Seer, Inc. Stock Price, News & Analysis

Seer, Inc. (Nasdaq: SEER) has appointed Meeta Gulyani to its Board of Directors. Gulyani, currently Executive Vice President at Merck KGaA, brings extensive experience in life sciences. Her leadership is expected to support Seer's mission in proteomics, which aims to unlock new insights in healthcare. Gulyani has held significant roles at Roche and possesses a strong background in strategy, business development, and transformation. Seer's Proteograph Product Suite is at the forefront of proteomic analysis, enhancing research capabilities in various laboratories.

Seer, a life sciences company listed on Nasdaq as SEER, announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. A pre-recorded presentation will be available online starting November 22, 2021. Additionally, Seer will conduct investor meetings on December 1 and 2, 2021. The company is focused on its Proteograph Product Suite, designed for efficient and deep proteomic analysis, accessible to many laboratories. The suite is for research use only and not intended for diagnostic procedures.

Seer, Inc. reported third-quarter 2021 revenues of $2.2 million, a significant increase from $72,000 in Q3 2020, driven by the Proteograph Product Suite. Product-related revenue reached $1.6 million, with a gross profit of $1.2 million and a gross margin of 54%. However, the company's operating expenses surged to $19.6 million, resulting in a net loss of $18.4 million. As of September 30, 2021, Seer held approximately $506.6 million in cash and investments. The company is on track for a Broad Release of its product in early 2022.

Seer, Inc. (Nasdaq: SEER) has appointed Rachel Haurwitz, Ph.D., CEO of Caribou Biosciences, to its Board of Directors effective November 8, 2021. Haurwitz's extensive experience in genome editing is expected to bolster Seer's mission in proteomics. David Singer will step down from the board, marking a significant leadership transition. The addition of Haurwitz, a recognized figure in the biotechnology field, reflects Seer’s commitment to advancing its innovative Proteograph technology aimed at enhancing biological insights.

Seer, Inc. (Nasdaq: SEER) will announce its Q3 2021 financial results on November 9, 2021, after market close, followed by a conference call at 1:30 p.m. PT. The company is known for its innovative Proteograph™ Product Suite, designed for advanced proteomic analysis. This system utilizes proprietary nanoparticles and automation to facilitate in-depth research quickly and efficiently. The results and details will be accessible via Seer’s investor website.

Seer, a life sciences company specializing in proteomics, announced its participation in the Morgan Stanley Global Healthcare Conference. The virtual fireside chat is scheduled for September 9 at 9:30 a.m. Pacific Time. A live webcast will be accessible on Seer's investor website, with an archived replay available post-conference. Seer’s Proteograph Product Suite provides deep proteomic analysis using innovative technology to enhance research capabilities across various labs. This product is intended for research use only and not for diagnostic procedures.

Seer, Inc. (Nasdaq: SEER) reported significant growth in Q2 2021, with revenues surging to $1.3 million from $71,000 in Q2 2020, driven by sales of the Proteograph Product Suite. The company booked initial revenue and expanded its customer base, including its first international client, while entering the Chinese market through a partnership with Enlight Medical. However, operating expenses increased to $17.4 million, resulting in a net loss of $16.6 million. As of June 30, 2021, Seer held approximately $518 million in cash and investments.

Seer (NASDAQ: SEER) partnered with Enlight Medical to distribute its Proteograph Product Suite in China. This collaboration aims to enhance access to Seer’s innovative proteomics platform in one of the world's fastest-growing life sciences markets. The partnership enables Enlight Medical to leverage its industry experience and connections to facilitate sales and marketing. Seer’s Proteograph technology targets biomarker discovery, essential for research in oncology and other diseases. This agreement is expected to accelerate Seer’s commercial presence in China, meeting the rising healthcare demands in the region.

Seer, Inc. (Nasdaq: SEER) will announce its Q2 2021 financial results on August 12, 2021, after market close. A conference call is scheduled for 1:30 PM PT / 4:30 PM ET. Live audio will be available on Seer’s investor website, with replays following the event. The company is known for its Proteograph Product Suite, designed for deep proteomic analysis, revolutionizing research with easy-to-use tools for labs. Seer emphasizes that the Proteograph is for research only and not for diagnostics.